High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer

E-ISSN： 1873-5576|12|6|693-702

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.12, Iss.6, 2012-07, pp. : 693-702

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer

Current Cancer Drug Targets, Vol. 10, Iss. 7, 2010-11 ,pp. : 772-781

Bentham Science Publishers

Access to resources Recommend Favorite

High Expression of CXCR4 and CXCR7 Predicts Poor Survival in Gallbladder Cancer

By Yao X Zhou L Han S Chen Y

The Journal of International Medical Research, Vol. 39, Iss. 4, 2011-07 ,pp. : 1253-1264

Field House Publishing

Access to resources Recommend Favorite

Sunitinib surpasses standard therapy for metastatic renal cancer

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3435-3443

Blackwell Publishing

Access to resources Recommend Favorite

Sunitinib cost effective for renal cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 532, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite